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Middle East Respiratory Syndrome (MERS) is a viral respiratory illness caused by a coronavirus called MERS-CoV. It was first reported in Saudi Arabia in 2012 and has since spread to various Middle Eastern, European, North African and Asian countries. In this case study, we report a 54-year-old man who became the first laboratory-confirmed case of MERS-CoV infection in Malaysia, as well as in Asia (outside Middle East), and also the first death in this region due to the infection. He had underlying diabetes mellitus, complaining of cough, fever and shortness of breath for 2 days with recent visit to Middle East. Chest radiograph show a consolidation at the right midzone. Blood investigations showed a normal haemoglobin and white cell count with platelet 127 000/mm^3^, creatinine 132 micromol/L, urea 11 mmol/L, CK 935 mmol/L, ALT 62 mmol/L and AST 145 mmol/L. He was started on intravenous Amoxycillin-Clavulanate acid, oral Erythromycin, and oral Oseltamivir for pneumonia and throat swab was sent for MERS-CoV PCR analysis. His condition deteriorated in ward with worsening respiratory failure. CTPA was done to rule out pulmonary embolism, which showed no pulmonary embolism but bilateral gross consolidation, more on the right, in keeping with an infective process. Antibiotics were changed to intravenous Ceftriaxone and Azithromycin; however, there was continuous deterioration and patient succumbed to his illness on day 4 of admission. His throat swab was later traced back to be positive for MERS-CoV, while his sputum was negative for bacterial cultures.
